Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The Food and Drug Administration today approved Eli Lilly’s weight-loss treatment ... Regulators can expand approval for medicines if new data shows them to be effective in other therapeutic ...

The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the ...

21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co ... easing knee arthritis pain to curbing asthma. Friday's FDA approval of Zepbound for treating moderate to severe ...

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

Shelby Knowles/Bloomberg via Getty The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication ... also supports the FDA’s new authorization.

The FDA on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug ...

The approval is the second indication for Zepbound, which was approved for weight loss ... the new FDA green light doesn’t expand the number of people who may be eligible for the drug, since ...